[Clinico-morphological characteristics and results of treatment of endometrioid cystadenocarcinoma of the ovary]

Voprosy onkologii · 1983 · vol. 29(12) , pp. 49–56 · PMID:6420990
Observational public-domain-us
View on PubMed
⚙ AI-generated summary by qwen3.7-flash, 2026-08-14 ⓘ

This study compared endometrioid and serous ovarian cystadenocarcinoma, finding that the former is associated with hyperestrogenism, fewer metastases, better survival rates, and greater efficacy of progestin treatment.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

Clinico-morphological peculiarities of endometrioid cystadenocarcinoma of the ovaries (105 cases) were compared with those of a more frequent serous one. Hyperestrogenism was more frequent in endometrioid cystadenocarcinoma, metastases, ascites and hydrothorax developing less frequently. Immediate and long-term results in endometrioid cystadenocarcinoma were better than in cases of serous one. When hormone-producing, both tumors metastasized less frequently and 5-year survival rates in such cases were relatively higher. Progestin treatment was effective in cases of endometrioid cystadenocarcinoma, particularly, in those of hormone-producing form.

My notes (saved in your browser only)

Condition tags

endometriosis

MeSH descriptors

Adenocarcinoma Cystadenocarcinoma Endometriosis Ovarian Neoplasms Adenocarcinoma Adenocarcinoma Adenocarcinoma Adenocarcinoma Antineoplastic Agents Antineoplastic Agents Antineoplastic Agents Castration Castration Combined Modality Therapy Combined Modality Therapy Cystadenocarcinoma Cystadenocarcinoma Cystadenocarcinoma Cystadenocarcinoma Endometriosis

Citation neighborhood (no data yet)

We don't have any in-corpus citations linked to this paper yet. The paper's references may be in our DB but unresolved to ``paper_id`` (resolution happens at ingest when the cited DOI matches a row we already have). Run the cross-source citation reconcile pass to retry.

Source provenance

europepmc
last seen: 2026-10-25T09:32:14.900964+00:00
pubmed
last seen: 2026-10-08T21:58:08.863946+00:00
License: public-domain-us · commercial use OK · attribution required
Courtesy of the U.S. National Library of Medicine